Sowell Financial Services LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 6,787 shares of the company's stock, valued at approximately $5,605,000.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Montecito Bank & Trust grew its position in Eli Lilly and Company by 1.1% during the 1st quarter. Montecito Bank & Trust now owns 10,406 shares of the company's stock worth $8,594,000 after purchasing an additional 113 shares during the last quarter. M.E. Allison & CO. Inc. lifted its stake in shares of Eli Lilly and Company by 12.4% during the first quarter. M.E. Allison & CO. Inc. now owns 1,487 shares of the company's stock worth $1,228,000 after buying an additional 164 shares during the period. Northstar Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% during the first quarter. Northstar Group Inc. now owns 1,070 shares of the company's stock valued at $884,000 after buying an additional 17 shares during the last quarter. Brown Miller Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $288,000. Finally, 1900 Wealth Management LLC raised its stake in Eli Lilly and Company by 4.1% in the 1st quarter. 1900 Wealth Management LLC now owns 560 shares of the company's stock worth $462,000 after acquiring an additional 22 shares during the last quarter. Institutional investors own 82.53% of the company's stock.
Eli Lilly and Company Price Performance
Shares of LLY traded down $11.74 during trading hours on Monday, hitting $807.62. 2,819,360 shares of the stock were exchanged, compared to its average volume of 3,654,950. The stock's 50-day moving average price is $775.43 and its two-hundred day moving average price is $801.69. The company has a market cap of $765.41 billion, a price-to-earnings ratio of 68.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.58 earnings per share. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.
Wall Street Analysts Forecast Growth
LLY has been the topic of a number of research reports. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,011.37.
Read Our Latest Analysis on LLY
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
